Last reviewed · How we verify
NCT03942224: DeRIVE
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Phase 2 trial testing Bortezomib in Plasma Cell Myeloma in 49 participants. Participants enrolled and being followed up; not accepting new ones.
31 July 2025
Quick facts
| Lead sponsor | Emory University |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 49 |
| Start date | 3 July 2019 |
| Primary completion | 31 July 2025 |
| Estimated completion | 31 July 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Bortezomib (bortezomib) — full drug profile →
- Daratumumab (daratumumab) — full drug profile →
- Dexamethasone (dexamethasone) — full drug profile →
- Ixazomib (IXAZOMIB) — full drug profile →
Conditions studied
- Plasma Cell Myeloma — all drugs for Plasma Cell Myeloma →
Sponsor
Emory University
Who can join
18 and older, any sex, with Plasma Cell Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies how well daratumumab, ixazomib, and dexamethasone with or without bortezomib work in treating patients with newly diagnosed multiple myeloma. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ixazomib, dexamethasone, and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving daratumumab, ixazomib, and dexamethasone with or without bortezomib may work better in treating patients with multiple myeloma.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Daratumumab in untreated newly diagnosed multiple myeloma.
Abdallah N, Kumar SK. · · 2019 · cited 36× · PMID 31903177 · DOI 10.1177/2040620719894871 -
Post-Transplant Maintenance Treatment Options in Multiple Myeloma.
Karam D, Kumar S. · · 2021 · cited 8× · PMID 33615426 · DOI 10.1007/s40487-021-00143-7 -
Landscape of adenosine pathway and immune checkpoint dual blockade in NSCLC: progress in basic research and clinical application.
Wang R, Liu Z, Wang T, Zhang J, et al · · 2024 · cited 7× · PMID 38348050 · DOI 10.3389/fimmu.2024.1320244 -
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Rifkin RM, Girnius SK, Noga SJ, Birhiray RE, et al · · 2023 · cited 2× · PMID 37726298 · DOI 10.1038/s41408-023-00912-9
Verify or expand the search:
- PubMed search for NCT03942224
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bortezomib
Trials testing the same drug.
- NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
- NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
- NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
- NCT07224672 — A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an · Phase 2 · not yet recruiting
- NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting
Other recruiting trials for Plasma Cell Myeloma
Currently open trials in the same condition.
- NCT04876248 — Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Po · Phase 2 · active not recruiting
- NCT05561387 — Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Me · Phase 3 · recruiting
- NCT05892393 — Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma · Phase 1 · recruiting
- NCT05669989 — International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefi · Phase 2 · active not recruiting
- NCT05392946 — Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study · Phase 1, PHASE2 · active not recruiting
Other Emory University trials
Trials by the same sponsor.
- NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
- NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
- NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
- NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
- NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03942224 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Emory University
- Last refreshed: 21 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03942224.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing